[go: up one dir, main page]

FR14C0080I2 - Methode d'administration d'un anticorps - Google Patents

Methode d'administration d'un anticorps

Info

Publication number
FR14C0080I2
FR14C0080I2 FR14C0080C FR14C0080C FR14C0080I2 FR 14C0080 I2 FR14C0080 I2 FR 14C0080I2 FR 14C0080 C FR14C0080 C FR 14C0080C FR 14C0080 C FR14C0080 C FR 14C0080C FR 14C0080 I2 FR14C0080 I2 FR 14C0080I2
Authority
FR
France
Prior art keywords
antibody administration
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0080C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Millennium Pharmaceuticals Inc
Original Assignee
Genentech Inc
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Millennium Pharmaceuticals Inc filed Critical Genentech Inc
Publication of FR14C0080I1 publication Critical patent/FR14C0080I1/fr
Application granted granted Critical
Publication of FR14C0080I2 publication Critical patent/FR14C0080I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
FR14C0080C 2000-04-14 2014-11-13 Methode d'administration d'un anticorps Active FR14C0080I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55008200A 2000-04-14 2000-04-14
US09/748,960 US20010046496A1 (en) 2000-04-14 2000-12-27 Method of administering an antibody
PCT/US2001/012234 WO2001078779A2 (fr) 2000-04-14 2001-04-13 Methode d'administration d'un anticorps

Publications (2)

Publication Number Publication Date
FR14C0080I1 FR14C0080I1 (fr) 2014-12-19
FR14C0080I2 true FR14C0080I2 (fr) 2015-10-30

Family

ID=27069332

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0080C Active FR14C0080I2 (fr) 2000-04-14 2014-11-13 Methode d'administration d'un anticorps

Country Status (15)

Country Link
US (5) US20010046496A1 (fr)
EP (3) EP2298348B9 (fr)
JP (3) JP2003531129A (fr)
AU (1) AU2001251629A1 (fr)
BE (1) BE2017C009I2 (fr)
CA (1) CA2406220C (fr)
CY (3) CY1113489T1 (fr)
DK (2) DK1278543T3 (fr)
ES (2) ES2398096T3 (fr)
FR (1) FR14C0080I2 (fr)
LU (1) LUC00014I2 (fr)
MX (1) MXPA02010059A (fr)
NL (1) NL300702I1 (fr)
PT (1) PT2298348T (fr)
WO (1) WO2001078779A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003072040A2 (fr) 2002-02-25 2003-09-04 Elan Pharmaceuticals, Inc. Administration d'agents pour le traitement d'une inflammation
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR122019027974B1 (pt) 2002-05-02 2022-06-14 Wyeth Holdings Corporation Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
PL2177537T3 (pl) * 2004-01-09 2012-06-29 Pfizer Przeciwciała przeciw MadCAM
ES2690079T3 (es) 2004-09-03 2018-11-19 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
DE602006017373D1 (de) * 2005-07-08 2010-11-18 Pfizer Ltd Madcam-antikörper
CA2614622A1 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Nouvelle combinaison d'un anticorps anti-madcam et d'un inhibiteur de caspase anti-fibrotique pour le traitement de la fibrose du foie
WO2007007152A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
WO2008115504A2 (fr) * 2007-03-20 2008-09-25 Millennium Pharmaceuticals, Inc. Acides nucléiques codant une immunoglobuline humanisée qui se lie à l'intégrine a4b7
WO2009026117A2 (fr) * 2007-08-16 2009-02-26 Glaxo Group Limited Nouveaux composés
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
ES2533480T3 (es) * 2008-05-16 2015-04-10 F. Hoffmann-La Roche Ag Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7
CN103382222B (zh) * 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2012151247A2 (fr) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION POUR UN ANTICORPS ANTI-α4β7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012340621B2 (en) * 2011-11-23 2017-10-12 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EA201992881A3 (ru) * 2012-01-12 2020-12-30 Милленниум Фармасьютикалз, Инк. Композиция анти-47 антитела
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2016105572A1 (fr) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. Prévision du résultat de traitement avec un anticorps dirigé contre l'intégrine anti-α4β7
MX2018011169A (es) 2016-03-14 2018-12-06 Millennium Pharm Inc Metodo para prevenir la enfermedad del injerto contra huesped.
WO2017160700A1 (fr) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
CU20200002A7 (es) 2017-07-14 2020-11-30 Pfizer Anticuerpos contra madcam
US12492245B2 (en) * 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2024252368A2 (fr) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Procédés et compositions pour le traitement de la rectocolite hémorragique
WO2025149974A1 (fr) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Polythérapie avec un anticorps anti-alpha4bêta7
WO2025177214A1 (fr) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Méthodes thérapeutiques

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0318554B2 (fr) 1987-05-21 2005-01-12 Micromet AG Proteines mutifonctionnelles a cible predeterminee
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (fr) * 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
SK287601B6 (sk) * 1998-09-14 2011-03-04 Board Of Regents, The University Of Texas System Použitie protilátky alebo jej fragmentu viažuceho antigén na výrobu farmaceutickej kompozície na liečenie mnohonásobného myelómu a na inhibíciu resorpcie kostí

Also Published As

Publication number Publication date
US20200002423A1 (en) 2020-01-02
CY2014046I2 (el) 2016-04-13
JP2012184241A (ja) 2012-09-27
CY2014046I1 (el) 2016-04-13
EP3167902A1 (fr) 2017-05-17
US20140186345A1 (en) 2014-07-03
HK1054320A1 (en) 2003-11-28
EP1278543A2 (fr) 2003-01-29
CY1113489T1 (el) 2016-04-13
NL300702I2 (fr) 2016-01-28
AU2001251629A1 (en) 2001-10-30
NL300702I1 (fr) 2016-01-28
BE2017C009I2 (fr) 2017-09-22
EP2298348A1 (fr) 2011-03-23
ES2609689T3 (es) 2017-04-21
WO2001078779A2 (fr) 2001-10-25
EP1278543B1 (fr) 2012-09-19
PT2298348T (pt) 2017-01-04
ES2398096T3 (es) 2013-03-13
JP6021959B2 (ja) 2016-11-09
CY1118429T1 (el) 2017-06-28
US20010046496A1 (en) 2001-11-29
DK1278543T3 (da) 2013-01-14
JP2015083603A (ja) 2015-04-30
US20120034243A1 (en) 2012-02-09
EP3167902B1 (fr) 2020-07-29
CA2406220C (fr) 2019-02-12
JP2003531129A (ja) 2003-10-21
EP2298348B9 (fr) 2017-02-15
WO2001078779A3 (fr) 2002-07-04
EP2298348B1 (fr) 2016-10-12
LUC00014I2 (fr) 2017-06-19
CA2406220A1 (fr) 2001-10-25
DK2298348T3 (en) 2017-01-30
JP5764524B2 (ja) 2015-08-19
US20050095238A1 (en) 2005-05-05
MXPA02010059A (es) 2004-08-19
FR14C0080I1 (fr) 2014-12-19
LUC00014I1 (fr) 2017-04-18

Similar Documents

Publication Publication Date Title
FR14C0080I2 (fr) Methode d'administration d'un anticorps
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
DE60121953D1 (de) Herstellungsverfahren von arzneizubereitungen
EP1390741A4 (fr) Construction structurelle de bibliotheques d'anticorps humains
EP1396500A4 (fr) Anticorps anti-trail-r
IS5245A (is) Lyfjablanda úr ómeprasól
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
CY2014003I2 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
NO20071303L (no) Farmasoytiske preparater
EP1423431A4 (fr) Anticorps anti-vla-1
EE200200393A (et) Glüburiidi ravimkoostis
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20025450L (no) Ny farmasöytisk sammensetning
EP1423399A4 (fr) Chelateurs d'hydroxypyridonate et d'hydroxypyrimidinone
ID30187A (id) Dongkrak jenis pantagraf
EP1399187A4 (fr) Utilisations d'anticorps monoclonal 8h9
EP1542721A4 (fr) Anticorps "s" modifies
DE60126814D1 (de) Inhalation von stickoxid
EE200300218A (et) Latentse antitrombiin III valmistamise meetod
ITBO20000446A0 (it) Unita' e metodo di trasferimento di spezzoni di sigaretta .
DE60142051D1 (de) Herstellung von perfluorolefinen
FR2816843B1 (fr) Inhibiteurs de l'enzyme 5 alpha-reductase
FR2824092B1 (fr) Ensemble d'elements de construction
EP1335024A4 (fr) Anticorps inhibant l'activite vplf